UPDATE: NovoCure Ltd. (NVCR) PT Raised to $235 at Piper Sandler Following Bull vs. Bear Debate (CORRECT)

April 16, 2021 7:19 AM EDT
Get Alerts NVCR Hot Sheet
Price: $182.01 --0%

Rating Summary:
    7 Buy, 5 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 15 | New: 32
Trade Now! 
Join SI Premium – FREE
(Updated - April 16, 2021 9:16 AM EDT)

Piper Sandler analyst Jason Bednar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $235.00 (from $225.00) while maintaining an Overweight rating following Bull vs. Bear debate.

The analyst commented, "We are hosting a Bull vs. Bear style debate within the medtech group at Piper Sandler withNovoCure the focus of today's debate. Shares are up 15% ytd vs. +11% for the S&P, duelargely to a ~50% move higher earlier this week following a positive update regarding thecompany's Ph3 LUNAR trial. Even still, NVCR represents one of the more controversialstocks on our coverage list across a number of topics, with bulls pointing to NVCR beingone of the most catalyst-rich stories in medtech with a sizable opportunity for TTFields tobe a platform technology, while bears disagree with the potential applicability of TTFieldsin alternative indications and believe current valuation doesn't account for a number ofclinical, regulatory, and commercialization risks that exist. We plan to unpack these andother topics in our live debate later today."

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Standard & Poor's